Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has been assigned an average rating of “Hold” from the thirteen analysts that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $33.67.

A number of equities analysts have issued reports on the stock. ValuEngine cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 18th. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 18th. Finally, BidaskClub cut shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, April 11th.

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos sold 72,872 shares of the firm’s stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $15.34, for a total value of $1,117,856.48. Following the sale, the chief executive officer now owns 1,276,343 shares in the company, valued at $19,579,101.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 8.20% of the stock is currently owned by company insiders.

Several large investors have recently made changes to their positions in the business. SEI Investments Co increased its stake in shares of Vanda Pharmaceuticals by 4.0% in the first quarter. SEI Investments Co now owns 171,892 shares of the biopharmaceutical company’s stock valued at $3,158,000 after purchasing an additional 6,565 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Vanda Pharmaceuticals by 25.6% in the first quarter. Goldman Sachs Group Inc. now owns 830,735 shares of the biopharmaceutical company’s stock valued at $15,286,000 after purchasing an additional 169,200 shares during the period. Voya Investment Management LLC increased its stake in shares of Vanda Pharmaceuticals by 86.6% in the first quarter. Voya Investment Management LLC now owns 40,406 shares of the biopharmaceutical company’s stock valued at $743,000 after purchasing an additional 18,752 shares during the period. Geode Capital Management LLC increased its stake in shares of Vanda Pharmaceuticals by 7.1% in the first quarter. Geode Capital Management LLC now owns 639,094 shares of the biopharmaceutical company’s stock valued at $11,759,000 after purchasing an additional 42,468 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Vanda Pharmaceuticals by 19.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 436,312 shares of the biopharmaceutical company’s stock valued at $8,029,000 after purchasing an additional 72,121 shares during the period. Institutional investors own 99.33% of the company’s stock.

NASDAQ VNDA traded up $0.45 during trading hours on Monday, reaching $15.13. The company’s stock had a trading volume of 569,300 shares, compared to its average volume of 822,738. Vanda Pharmaceuticals has a 52 week low of $13.66 and a 52 week high of $33.44. The stock has a market capitalization of $777.51 million, a P/E ratio of 31.52 and a beta of 0.59.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.08). Vanda Pharmaceuticals had a return on equity of 8.07% and a net margin of 10.92%. The business had revenue of $47.71 million during the quarter, compared to the consensus estimate of $51.74 million. During the same period in the prior year, the business earned $0.14 EPS. The business’s revenue was up 9.5% on a year-over-year basis. On average, research analysts anticipate that Vanda Pharmaceuticals will post 0.06 earnings per share for the current year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Featured Article: Why investors pay attention to retained earnings

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.